Form 4: CFO Gifts Shares; NBIX Ownership Update

Neurocrine Biosciences CFO Matt Abernethy reported a gift of 2,249 common shares, reducing his direct beneficial ownership.

Summary

• Matt Abernethy, Chief Financial Officer of Neurocrine Biosciences Inc. (NBIX), reported a change in beneficial ownership.
• On March 4, 2026, Abernethy made a gift/charitable contribution of 2,249 shares of NBIX Common Stock.
• No value was received for the gifted shares, as it was not a market transaction.
• Following this transaction, Abernethy directly beneficially owns 42,808 shares of Common Stock.
• The reported beneficial ownership of 42,808 shares includes 176 shares purchased on February 27, 2026, through the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While a disposition of shares by a CFO, it was a gift rather than a market sale, and was partially offset by an earlier Employee Stock Purchase Plan acquisition.

Positives

• The transaction was a gift/charitable contribution, not a sale on the open market, indicating no direct intent to liquidate holdings for personal gain.
• The CFO also acquired 176 shares through the Employee Stock Purchase Plan on February 27, 2026, demonstrating continued participation in company equity programs.

Negatives

• Chief Financial Officer Matt Abernethy disposed of 2,249 shares of common stock through a gift, reducing his direct beneficial ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly gifts, are common and generally do not reflect operational performance or strategic shifts. The continued participation in the Employee Stock Purchase Plan suggests ongoing confidence in the company's equity by the CFO.

Stakeholder Impact

• Shareholders: A slight reduction in insider ownership due to the gift, but the impact is minimal given the nature of the transaction (gift vs. open market sale) and the CFO's remaining substantial holdings. The ESPP purchase indicates continued alignment of interests.

Key Dates

Recommendation

The filing details a routine insider transaction involving a gift of shares and an Employee Stock Purchase Plan acquisition. These events do not provide new material information to warrant a change in investment thesis for Neurocrine Biosciences, Inc. The overall impact on the company's fundamentals or strategic direction is negligible, thus a 'hold' recommendation is maintained.

Keywords

Neurocrine Biosciences, NBIX, Form 4, Insider Transaction, Matt Abernethy, CFO, Stock Gift, Beneficial Ownership, Employee Stock Purchase Plan